title: New challenges in kidney cancer therapy: sunitinib.
authors.affiliation: Department of Medical Oncology, AP-HP, Pitie-Salpetriere Hospital, Paris, France.
authors.forename: H
authors.initials: H
authors.lastname: Izzedine
authors.forename: B
authors.initials: B
authors.lastname: Billemont
authors.forename: F
authors.initials: F
authors.lastname: Thibault
authors.forename: O
authors.initials: O
authors.lastname: Rixe
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D002986:Clinical Trials as Topic; D005544:Forecasting; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011758:Pyrroles / Q000627:therapeutic use*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors; D000077210:Sunitinib; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D011758:Pyrroles; D011505:Protein-Tyrosine Kinases; D040262:Receptors, Vascular Endothelial Growth Factor; D000077210:Sunitinib